News

Vision Sensing Acquisition Corp. Announces Definitive Agreement and Plan of Merger with Mediforum Co., Ltd

The Combined Company Is Expected To Trade On Nasdaq Post-Closing Under A New Ticker SymbolMediforum is a leading biotechnology company…

2 months ago

Arvinas Appoints Jared Freedberg as General Counsel

Awards Mr. Freedberg an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4)NEW HAVEN, Conn., Jan. 16, 2024 (GLOBE NEWSWIRE)…

2 months ago

Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)

NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company…

2 months ago

Psyched Wellness Provides Update on Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - January 17, 2024) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or…

2 months ago

UTILITY therapeutics Ltd. Announces Financing Led by the AMR Action Fund and FDA Acceptance of PIVYA New Drug Application with Priority Review

UTILITY has received a Prescription Drug User Fee Act (PDUFA) target action date of April 24, 2024FDA granted Qualified Infectious…

2 months ago

PrestoDoctor Expands Its Cannabis Telemedicine Service to West Virginia

MESQUITE, NV / ACCESSWIRE / January 17, 2024 / Cannabis Sativa, Inc. (OTCQB:CBDS) announces that PrestoDoctor - the #1 patient-rated…

2 months ago

Bioz and Innovative Research Forge a Dynamic Partnership to Advance Research Excellence

PALO ALTO, CA / ACCESSWIRE / January 17, 2024 / Bioz, Inc., a leading Silicon Valley-based AI software company committed…

2 months ago

Revolutionizing Drug Development: Novigenix Unveils AI-Powered RNA Analysis for Immune Response Profiling

GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2024 / With cancer projected to escalate to 29 million cases by 2040[1],…

2 months ago

Poolbeg Pharma PLC Announces Further Data Shows POLB001 Potential in Cancer CRS

Further Data Confirms POLB 001's Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)Market opportunity estimated to be greater than US$1…

2 months ago